BridgeBio Pharma Inc R&D Day Transcript
Good morning, and welcome to BridgeBio Second Annual Virtual R&D Day. My name is Grace Rauh. I'm the Vice President of Communications at BridgeBio, and I want to thank all of you for joining us for this event.
We have an incredible agenda ahead of us today. We're going to be hearing from Richard Scheller, our Chairman of R&D, who will provide some opening remarks about human genetics and the important role that it plays in drug discovery. Next up, our Founder and CEO, Neil Kumar, who is going to be talking about what he calls BridgeBio's endless summer. You'll also hear from Cameron Turtle, our Chief Strategy Officer, who is going to be sharing an overview of our cardiorenal work before we take a deep dive into our cardiorenal programs, starting with our progress on transthyretin amyloidosis, known as ATTR, which is an underdiagnosed, rapidly progressive and ultimately fatal disease.
In that session, we will be joined by Jonathan Fox, Chief Medical Officer of BridgeBio Cardiorenal, who is going to be setting the stage for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
